Stay updated on Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.
Latest updates to the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.1%
- Check11 days agoChange DetectedA new publication has been added detailing study results on blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer, while several older entries from late 2022 have been removed.SummaryDifference4%
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
- Check32 days agoNo Change Detected
- Check47 days agoChange DetectedThe study has expanded to include 15 locations, and the software has been updated from version v2.9.7 to v2.10.0.SummaryDifference0.3%
- Check54 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check68 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
Stay in the know with updates to Biomarker Response to Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.